Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
logos LINCs Logo Mt Sinai Logo NIH Logo NCI Logo
Protein Page:
ATR (human)
rdtyret
p Phosphorylation
ac Acetylation
me Methylation
m1 Mono-methylation
m2 Di-methylation
m3 Tri-methylation
ub Ubiquitylation
sm Sumoylation
ne Neddylation
gl O-GlcNAc
ga O-GalNAc
pa Palmitoylation
ad Adenylation
sn S-Nitrosylation
ca Caspase cleavage
sc Succinylation

Overview
ATR a ser/thr kinase of the PIKK family most closely related to ATM. Activates checkpoint signaling upon genotoxic stresses such as ionizing radiation (IR), ultraviolet light (UV), or DNA replication stalling, thereby acting as a DNA damage sensor. Recognizes the substrate consensus sequence [ST]Q. Phosphorylates BRCA1, Chk1, MCM2, RAD17, RPA2, SMC1 and p53, which collectively inhibit DNA replication and mitosis and promote DNA repair, recombination and apoptosis. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX at sites of DNA damage, thereby regulating DNA damage response mechanism. Required for FANCD2 ubiquitination. Critical for maintenance of fragile site stability and efficient regulation of centrosome duplication. Note: This description may include information from UniProtKB.
Protein type: Membrane protein, integral; EC 2.7.11.1; Protein kinase, atypical; Kinase, protein; Kinase, lipid; Protein kinase, Ser/Thr (non-receptor); ATYPICAL group; PIKK family; ATR subfamily
Chromosomal Location of Human Ortholog: 3q23
Cellular Component: chromosome; Golgi apparatus; nuclear chromosome, telomeric region; nucleoplasm; PML body; XY body
Molecular Function: ATP binding; DNA binding; MutLalpha complex binding; MutSalpha complex binding; protein binding; protein kinase activity; protein serine/threonine kinase activity
Biological Process: cell cycle; DNA damage checkpoint; DNA repair; DNA replication; double-strand break repair; double-strand break repair via homologous recombination; multicellular organismal development; negative regulation of DNA replication; peptidyl-serine phosphorylation; positive regulation of DNA damage response, signal transduction by p53 class mediator; positive regulation of telomere maintenance via telomerase; protein amino acid autophosphorylation; regulation of protein binding; response to DNA damage stimulus; response to drug
Disease: Cutaneous Telangiectasia And Cancer Syndrome, Familial; Seckel Syndrome 1
Reference #:  Q13535 (UniProtKB)
Alt. Names/Synonyms: ataxia telangiectasia and Rad3 related; Ataxia telangiectasia and Rad3-related protein; ATR; FRAP-related protein 1; FRAP-related protein-1; FRP1; MEC1; MEC1, mitosis entry checkpoint 1, homolog; protein kinase ATR; Rad3 related protein; SCKL; SCKL1; Serine/threonine-protein kinase ATR
Gene Symbols: ATR
Molecular weight: 301,367 Da
Basal Isoelectric point: 7.17  Predict pI for various phosphorylation states
CST Pathways:  Apoptosis Regulation  |  G1/S Checkpoint  |  G2/M DNA Damage Checkpoint  |  Mitochondrial Control of Apoptosis
Protein-Specific Antibodies or siRNAs from Cell Signaling Technology® Total Proteins
Select Structure to View Below

ATR

Protein Structure Not Found.

Substrate Sequence Logo
Sequence Logo

STRING  |  cBioPortal  |  CCLE  |  Wikipedia  |  Reactome  |  neXtProt  |  Protein Atlas  |  BioGPS  |  Scansite  |  KinBase  |  Pfam  |  ENZYME  |  Phospho.ELM  |  NetworKIN  |  GeneCards  |  UniProtKB  |  Entrez-Gene  |  GenPept  |  Ensembl Gene  |  Ensembl Protein


Sites Implicated In
cell growth, altered: S428‑p
enzymatic activity, induced: S428‑p, T1989‑p
molecular association, regulation: S428‑p, T1989‑p

Modification Sites and Domains  
Click here to view other types of protein modifications

Modification Sites in Parent Protein, Orthologs, and Isoforms  
 

Show Multiple Sequence Alignment


 LTP 

LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.


 HTP 

HTP: The number of records in which this modification site was assigned using ONLY proteomic discovery-mode mass spectrometry.


       human

► Hide Isoforms
 
0 1 S20 PALRELGSATPEEyN
0 2 Y26‑p GSATPEEyNTVVQkP
0 1 T28 ATPEEyNTVVQkPRQ
0 2 K32‑ub EyNTVVQkPRQILCQ
0 1 S61‑p ELVKKTDsQPTSVML
1 0 Y291‑p DTDQLKLyEEPLSKL
1 0 Y310‑p FPFEAEAyRNIEPVy
0 1 Y317‑p yRNIEPVyLNMLLEK
11 7 S428‑p SSNSDGIsPKRRRLs
1 90 S435‑p sPKRRRLsssLNPsk
0 51 S436‑p PKRRRLsssLNPskR
0 7 S437‑p KRRRLsssLNPskRA
0 2 S441‑p LsssLNPskRAPKQT
0 1 K442‑ub sssLNPskRAPKQTE
0 1 T533‑p KKPSVVItWMSLDFY
0 1 S580 LIYMQVNSSFEDHIL
0 1 S581 IYMQVNSSFEDHILE
0 1 K746‑ub DLFCRNLkATSQHEC
0 1 K851‑ub ELFVLRMkEAYTHAQ
0 2 K866‑ub ISRNNELkDTLILTT
0 1 S919‑p RALVAAKsVKLQSFF
0 1 T952‑p QMTALPNtPCQNADV
0 3 K1005‑ub LLPDLAAkAsPAASA
0 1 S1007‑p PDLAAkAsPAASALI
0 1 N1024 LGKQLNVNRREILIN
0 1 Y1122‑p SPELMADyLQPKLLG
0 1 S1140‑p FFNMQLLsSSVGIED
0 1 K1173‑ac HVSSVRVkMMTTLRT
0 1 K1185‑ub LRTGLRFkDDFPELC
0 1 T1275‑p LQEYRKEtSESTDLQ
0 1 Y1312 TSLKETLYKNQEKLI
1 0 S1333‑p ETVEPIIsQLVTVLL
1 0 T1566‑p DDQHTINtQDIASDL
1 0 T1578‑p SDLCQLStQTVFSML
1 0 T1589‑p FSMLDHLtQWARHKF
0 1 K1613‑ub HSKSNRNkVDSMVST
0 4 S1645‑p QDTLAVAsFRSKAYT
0 2 K1703‑ub RKAEPSLkEQILEHE
0 3 K1824‑ub TAFYDSLkLVRAEQI
0 1 S1871‑p IKPLFQHsPGDSsQE
0 2 S1876‑p QHsPGDSsQEDSLNW
0 1 K1897‑ub TQNSYRAkEPILALR
8 34 T1989‑p LCFPENEtPPEGKNM
0 1 S2186‑p MTAVSKSsyPMRVNR
0 1 Y2187‑p TAVSKSsyPMRVNRC
0 1 T2219 VGDATRLTDKLLELC
0 1 S2313‑p LQKPKKIsLKGSDGK
0 1 K2404‑ub KGVYMTGkELRQCML
0 1 K2567‑ub DPLVEWSkPVKGHSK
0 2 K2587‑ub TGEVVNEkAKTHVLD
0 2 K2604‑ub QRLQGVIkTRNRVTG
2853 : Phospho-ATR (Ser428) Antibody
  ATR iso2  
S20 PALRELGSATPEEYN
Y26 GSATPEEYNTVVQKP
T28 ATPEEYNTVVQKPRQ
K32 EYNTVVQKPRQILCQ
S61 ELVKKTDSQPTSVML
Y291 DTDQLKLYEEPLSKL
Y310 FPFEAEAYRNIEPVY
Y317 YRNIEPVYLNMLLEK
S428 SSNSDGISPKRRRLS
S435 SPKRRRLSSSLNPSK
S436 PKRRRLSSSLNPSKR
S437 KRRRLSSSLNPSKRA
S441 LSSSLNPSKRAPKQT
K442 SSSLNPSKRAPKQTE
T469 KKPSVVITWMSLDFY
S516 LIYMQVNSSFEDHIL
S517 IYMQVNSSFEDHILE
K682 DLFCRNLKATSQHEC
K787 ELFVLRMKEAYTHAQ
K802 ISRNNELKDTLILTT
S855 RALVAAKSVKLQSFF
T888 QMTALPNTPCQNADV
K941 LLPDLAAKASPAASA
S943 PDLAAKASPAASALI
N960 LGKQLNVNRREILIN
Y1058 SPELMADYLQPKLLG
S1076 FFNMQLLSSSVGIED
K1109 HVSSVRVKMMTTLRT
K1121 LRTGLRFKDDFPELC
T1211 LQEYRKETSESTDLQ
Y1248 TSLKETLYKNQEKLI
S1269 ETVEPIISQLVTVLL
T1502 DDQHTINTQDIASDL
T1514 SDLCQLSTQTVFSML
T1525 FSMLDHLTQWARHKF
K1549 HSKSNRNKVDSMVST
S1581 QDTLAVASFRSKAYT
K1639 RKAEPSLKEQILEHE
K1760 TAFYDSLKLVRAEQI
S1807 IKPLFQHSPGDSSQE
S1812 QHSPGDSSQEDSLNW
K1833 TQNSYRAKEPILALR
T1925 LCFPENETPPEGKNM
S2122 MTAVSKSSYPMRVNR
Y2123 TAVSKSSYPMRVNRC
T2155 VGDATRLTDKLLELC
S2249 LQKPKKISLKGSDGK
K2340 KGVYMTGKELRQCML
K2503 DPLVEWSKPVKGHSK
K2523 TGEVVNEKAKTHVLD
K2540 QRLQGVIKTRNRVTG
  mouse

 
S20‑p PALRELGsATPEEyN
Y26‑p GsATPEEyNtVVQKP
T28‑p ATPEEyNtVVQKPRQ
K32 EyNtVVQKPRQILCQ
A61 ELVKKTDAQPTSVML
Y294 DADQLKLYEEPLSKL
Y313 FPFEAEAYRNIEPVY
Y320 YRNIEPVYLNVLLEK
S431‑p SGNNDEVsPKRRKLs
S438‑p sPKRRKLsSSLSSYK
S439 PKRRKLsSSLSSYKK
S440 KRRKLsSSLSSYKKP
Y444 LsSSLSSYKKPSRQP
K445 sSSLSSYKKPSRQPE
T536 KKPPVVVTWMSLDFY
S583‑p LMYMQVKssFKDHVL
S584‑p MYMQVKssFKDHVLE
K746 DLFSKNLKATSQHEC
K851 ELFVLRMKEAYTHAQ
K866 IARNNELKDTLILTT
S919 RALVAAKSVKLQNFF
A952 QMTALPSAPCQSSEI
K1005 LLPDLAAKASPAASA
S1007 PDLAAKASPAASALI
S1024‑p LGKQLNVsRREILIN
Y1122 SPELMADYLQPKLLG
S1140 FFNMQLLSSSVGIED
K1173 HVSSVRVKMMTTLRT
K1185 LRTGLRFKDDFPELC
T1275 LQEYRKETSETTDLQ
Y1312‑p TSLKETLyKNQEKLI
S1333 ETVEPVISQLVTVIL
T1566 DEQHAISTQDSASDL
T1578 SDLCQLSTQTVFSVL
T1589 FSVLDHLTQWARHKF
- gap
S1639 QDTLAVASFRSKAYT
K1697 RKAEPSLKEQILEHE
K1818 TTFYDTLKLVRAEQI
S1865 LKPLFRKSPGDSCNE
C1870 RKSPGDSCNEDSLNW
K1891 TQNSYRAKEPILALR
S1983 LCFPENKSPSESKHM
S2180 MTAVSKSSYPMRVNR
Y2181 TAVSKSSYPMRVNRC
T2213‑p VGDATRLtDKLLELC
S2304 LQKPKKISLKGSDGK
K2395 KGVYMTGKELRQCML
K2558 DPLVEGSKPVKGHSK
K2578 TGEVVNEKAKTHVLD
K2595 QRLQGVIKTRNRVTG
2853 : Phospho-ATR (Ser428) Antibody
  rat

 
S20 PALRELGSATPEEYN
Y26 GSATPEEYNTVVQKP
T28 ATPEEYNTVVQKPRQ
K32 EYNTVVQKPRQILCQ
T61 ELVKKTDTQPTSVML
Y294 DADQLKLYEEPLSKL
Y313 FPFEAEAYRNIEPVY
Y320 YRNIEPVYLNVLLEK
S431 RGSNDGVSPKRRRLS
S438 SPKRRRLSSSLSSYK
S439 PKRRRLSSSLSSYKR
S440 KRRRLSSSLSSYKRP
Y444 LSSSLSSYKRPSRQS
K445 SSSLSSYKRPSRQSE
T536 KKPPVVITWMSLDFY
S583 LMYIQVKSSFQDHVL
S584 MYIQVKSSFQDHVLE
K747 DLFCKNLKATSQHEC
K852 ELFVLRMKEAYTHAQ
K867 ISRSNELKDTLILTT
S920 RALVAAKSVKLQNFF
T953 QMTALPSTPCQTAEM
K1006 LLPDLAAKASPAASA
S1008 PDLAAKASPAASALI
N1025 LGKQLNVNRREILIN
Y1123 SPELMADYLQPKLLG
S1141 FFNMQLLSSSVGIED
K1174 HVSSVRVKMMTTLRT
K1186 LRTGLRFKDDFPELC
T1276 LQEYRKETSESTDLQ
Y1313 TSLKETLYKNQEKLI
S1334 ETVEPVISQLVTVIL
T1567 DDQHAISTQDSASDL
T1579 SDLCQLSTQTVFSML
T1590 FSMLDHLTQWARHKF
K1614 QNKPKGGKVNYPVSS
S1646 QDTLAVASFRSKAYT
K1704 RKAEPSLKEQILEHE
K1825 TAFYDTLKLVRAEQI
F1872 LKPLFHKFPGDSCNE
C1877 HKFPGDSCNEDSLNW
K1898 TQNSYRAKEPILALR
S1990 LCFPENKSPTESKHM
S2187 MTAVSKSSYPMRVNR
Y2188 TAVSKSSYPMRVNRC
T2220 VGDATRLTDKLLELC
S2311 LQKPKKISLKGSDGK
K2402 KGVYMTGKELRQCML
K2565 DPLVEWSKPVKGHSK
K2585 TGEVVNEKAKTHVLD
K2602 QRLQGVIKTRNRVTG
Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.